Aclaris Therapeutics (ACRS) Share-based Compensation (2014 - 2026)

Aclaris Therapeutics' Share-based Compensation history runs 13 years deep, the most recent figure standing at $19.7 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 7063.64% year-over-year to $19.7 million in Q1 2026; TTM through Mar 2026 was $19.7 million, a 243.86% increase from a year earlier, with the FY2025 full-year figure at $12.4 million, up 23.84% from the prior year.
• Share-based Compensation advanced to $19.7 million in Q1 2026 per ACRS's latest filing, from $2.9 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $19.7 million in Q1 2026 and bottomed at -$19.3 million in Q4 2023.
• The 5-year median for Share-based Compensation is $3.0 million (2024), against an average of $3.7 million.
• Across the five-year window, Share-based Compensation sank 500.66% in 2023 and jumped 7063.64% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $4.8 million in 2022, then sank by 500.66% to -$19.3 million in 2023, then surged by 97.65% to -$453000.0 in 2024, then jumped by 745.92% to $2.9 million in 2025, then surged by 573.27% to $19.7 million in 2026.
• Per Business Quant, the three latest ACRS Share-based Compensation figures stand at $19.7 million (Q1 2026), $2.9 million (Q4 2025), and $2.9 million (Q3 2025).